12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Etirinotecan pegol: Phase II started

Nektar said investigators at Stanford Cancer Institute began an open-label, U.S. Phase II trial to evaluate NKTR-102 every 3 weeks in about 20 patients with bevacizumab-resistant...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >